Cargando…

Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study

Introduction: Venous thromboembolism (VTE) is the primary cause of preventable death in hospitalized patients in the United States. This is a cross-sectional study with a brief cost analysis of thromboprophylaxis with rivaroxaban and enoxaparin in acutely ill medical inpatients. Methods: The study i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenci Marques, Gustavo, De Franca, Ana Carolina, Saito, Ana Carolina, Hornung, Fabiana L, Motter, Ana Carolina, Falzoni Pontello, Ana Carolina, Fontana, Helena, Gasparetto, Juliano, Zequinão, Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262521/ https://www.ncbi.nlm.nih.gov/pubmed/34268028 http://dx.doi.org/10.7759/cureus.15497

Ejemplares similares

Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review
por: Zequinão, Tiago, et al.
Publicado: (2020)

Thromboprophylaxis in Patients With Cancer and COVID-19
por: Lecumberri, Ramón, et al.
Publicado: (2022)

Drug-Induced Liver Injury Caused by Amoxicillin/Clavulanate
por: Ferreira, Inês, et al.
Publicado: (2020)

Overuse and underuse of thromboprophylaxis in medical inpatients
por: Kocher, Barbara, et al.
Publicado: (2023)

Characterization of adverse drug events identified by trigger in Brazilian pediatric inpatients()
por: Silva, Lunara Teles, et al.
Publicado: (2019)

Successful Resolution of a Large Left Ventricular Thrombus with Rivaroxaban
por: DeCampos, Diana, et al.
Publicado: (2020)

Septic Arthritis and Bacteremia Due to Infection by Pasteurella canis
por: Nascimento, Bruna, et al.
Publicado: (2021)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
por: Gómez-Outes, Antonio, et al.
Publicado: (2012)

A broad-spectrum beta-lactam-sparing stewardship program in a middle-income country public hospital: antibiotic use and expenditure outcomes and antimicrobial susceptibility profiles
por: Zequinao, Tiago, et al.
Publicado: (2020)

Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome
por: Arora, Shreya, et al.
Publicado: (2021)

Sudden Loss of Vision: An Insight into Rivaroxaban
por: Jain, Akriti G, et al.
Publicado: (2019)

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?
por: Xavier, Flávia Dias, et al.
Publicado: (2016)

Thromboprophylaxis for medical inpatients with coronavirus disease 2019
por: Dalager-Pedersen, M., et al.
Publicado: (2020)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Thromboprophylaxis and anticoagulation for inpatients with COVID-19 in 2022 and beyond
por: Dalager-Pedersen, Michael
Publicado: (2022)

The Use of Rivaroxaban for Unprovoked Pulmonary Embolism in the Setting of Antithrombin Deficiency
por: Gryn, Oscar J, et al.
Publicado: (2020)

Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh
por: Arishi, Ghazi I, et al.
Publicado: (2022)

Solvent-Induced Raynaud’s Phenomenon
por: Rodrigues, Helena, et al.
Publicado: (2023)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial
por: Kröll, Dino, et al.
Publicado: (2023)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Diffuse Alveolar Hemorrhage: An Unexpected Effect After Taking Acetylsalicylic Acid
por: Gomes, Mariana M, et al.
Publicado: (2022)

Thromboprophylaxis in elective spinal surgery: A protocol for systematic review
por: Colomina, María J., et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Survival prognosis of newborns from an intensive care unit through the SNAP-PE II risk score
por: Lima, Renato Oliveira, et al.
Publicado: (2020)

Adult-Onset Still’s Disease: Typical Presentation, Delayed Diagnosis
por: Seco, Tiago, et al.
Publicado: (2020)

A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban
por: Asleson, Louise, et al.
Publicado: (2022)

Loss of Seizure Control in a Patient With Vitamin D Deficiency and Phenytoin-Induced Hypocalcemia
por: Branco, Tiago, et al.
Publicado: (2022)

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021)

Treatment Failure of Cerebral Venous Thrombosis With Rivaroxaban: A Case Report and Narrative Review
por: Mohamed, Mustafa, et al.
Publicado: (2022)

Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review
por: Ramphall, Shivana, et al.
Publicado: (2022)

Underuse of medical thromboprophylaxis in mobile elderly inpatients: The SWITCO65+ cohort
por: Blondon, Marc, et al.
Publicado: (2020)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ho53lnkllhm6kug30nko6nu3ge